Every New York stock exchange trading day I’m posting a daily dividend stock or fund review. I’ll share the three chief qualities of just one equity or fund that could be selected for a dividend stock portfolio I’ve named the Safari to Sweet Success.

This week my Safari portfolio seeks a company in the healthcare sector. 

That sector includes ten industries all related to testing, diagnosing and treating what ails us. The healthcare industries are: biotechnology; diagnostics & research; drug manufacturers – major; drug manufacturers – specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices, medical distribution; medical supplies.

Today I’m reviewing a biotechnology company named Sirtex Medical Limited. Its trading ticker symbol is SXMDF. 

Sirtex Medical Limited is an Australian oncology-focused medical device company. The company offers a novel embolic radiation therapy device called SIR-Spheres microspheres used in targeted radiation therapy for treatment of liver tumors.

The company is headquartered in North Sydney, Australia. And its sale to Varian as agreed in January is pending,

I use three primary keys to gauge dividend equities or funds like Sirtex Medical Limited (SXMDF): 

(1) Price

(2) Dividends

(3) Returns

Those three primary keys, however, best tell whether a company has made, is making, and will make money. 

SXMDF Price

Sirtex Medical’s price at yesterday’s market close was $21.66 per share. A year ago its price was $11.60. So it gained$10.06 per share in the past year.No doubt bolstered by the tender offer of purchase by Varian. The sale is subject to shareholder approval, so no closing date is yet known.

If SXMDF does as well this coming year its value will increase from $21.66 to $31.72, or about 46%. The Varian Offer valued shares at $28.06. or up 29.5%

SXMDF Dividends

Sirtex Medical’s most recent annual dividend was $0.24 declared August 12th and paid October 18th.